Literature DB >> 18199437

History of the FIGO cancer staging system.

Franco Odicino1, Sergio Pecorelli, Lucia Zigliani, William T Creasman.   

Abstract

The main objectives of any good staging system - essential to an evidence-based approach to cancer - are: to aid the clinician in planning treatment; to provide indication of prognosis; to assist the physician in evaluating the results of treatment; to facilitate the exchange of information between treatment centers, thus disseminating knowledge; and to contribute to continuing investigations into human malignancies. A good staging system must have 3 basic characteristics: it must be valid, reliable, and practical. The first staging system for gynecological cancers appeared around the turn of the 20th century and applied to the carcinoma of the cervix uteri-the most common cancer affecting women in high income countries at that time. The classification and staging of the other gynecological malignancies was not put forward until the 1950s. Over the years, these staging classifications - with the exception of cervical cancer and gestational trophoblastic neoplasia - have shifted from a clinical to a surgical-pathological basis. This paper reviews the history of the International Federation of Gynecology and Obstetrics (FIGO) cancer staging system, how it was developed, and why.

Entities:  

Mesh:

Year:  2008        PMID: 18199437     DOI: 10.1016/j.ijgo.2007.11.004

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  43 in total

1.  The TNM classification of breast cancer: need for change.

Authors:  Paolo Arnone; Stefano Zurrida; Giuseppe Viale; Silvia Dellapasqua; Emilia Montagna; Paola Arnaboldi; Mattia Intra; Umberto Veronesi
Journal:  Updates Surg       Date:  2010-10

2.  Diffusion-weighted and diffusion-tensor imaging of normal and diseased uterus.

Authors:  Duygu Kara Bozkurt; Murat Bozkurt; Mehmet Ali Nazli; Ilhan Nahit Mutlu; Ozgur Kilickesmez
Journal:  World J Radiol       Date:  2015-07-28

3.  Integration of prostate cancer clinical data using an ontology.

Authors:  Hua Min; Frank J Manion; Elizabeth Goralczyk; Yu-Ning Wong; Eric Ross; J Robert Beck
Journal:  J Biomed Inform       Date:  2009-06-02       Impact factor: 6.317

4.  International Federation of Gynecology and Obstetrics (FIGO) staging system revised: what should be considered critically for gynecologic cancer?

Authors:  Hee Seung Kim; Yong Sang Song
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

5.  Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment.

Authors:  Joyce N Barlin; Robert A Soslow; Megan Lutz; Qin C Zhou; Caryn M St Clair; Mario M Leitao; Alexia Iasonos; Martee L Hensley; Richard R Barakat; Xavier Matias-Guiu; Nadeem R Abu-Rustum
Journal:  Int J Gynecol Cancer       Date:  2013-11       Impact factor: 3.437

6.  Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative.

Authors:  Farzana Pashankar; Juliet P Hale; Ha Dang; Mark Krailo; William E Brady; Carlos Rodriguez-Galindo; James C Nicholson; Matthew J Murray; Deborah F Bilmire; Sara Stoneham; G Suren Arul; Thomas A Olson; Daniel Stark; Furqan Shaikh; James F Amatruda; Allan Covens; David M Gershenson; A Lindsay Frazier
Journal:  Cancer       Date:  2015-10-20       Impact factor: 6.860

7.  Loss of beclin 1 expression in ovarian cancer: A potential biomarker for predicting unfavorable outcomes.

Authors:  Toshiko Minamoto; Kentaro Nakayama; Kohei Nakamura; Hiroshi Katagiri; Razia Sultana; Tomoka Ishibashi; Masako Ishikawa; Hitomi Yamashita; Kaori Sanuki; Kouji Iida; Satoru Nakayama; Yoshiro Otsuki; Noriyuki Ishikawa; Satoru Kyo
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

8.  Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.

Authors:  Justyna Mikuła-Pietrasik; Paweł Uruski; Kinga Matuszkiewicz; Sebastian Szubert; Rafał Moszyński; Dariusz Szpurek; Stefan Sajdak; Andrzej Tykarski; Krzysztof Książek
Journal:  Cell Oncol (Dordr)       Date:  2016-07-21       Impact factor: 6.730

9.  Characterizing gradient echo signal decays in gynecologic cancers at 3T using a Gaussian augmentation of the monoexponential (GAME) model.

Authors:  Pelin A Ciris; Mukund Balasubramanian; Antonio L Damato; Ravi T Seethamraju; Clare M Tempany-Afdhal; Robert V Mulkern; Akila N Viswanathan
Journal:  J Magn Reson Imaging       Date:  2016-03-12       Impact factor: 4.813

10.  Post-radiotherapy hysterectomy does not benefit females with cervical adenocarcinoma.

Authors:  Elen Cristiane Augusto Souza; Daniel Zaidan Santos; Jose Carlos Campos Torres; Diama Bhadra Vale; Joana Froes Bragança; Julio Cesar Teixeira
Journal:  Mol Clin Oncol       Date:  2020-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.